Searched for
NEOVASCULAR
Biocon Biologics secures market entry for Yesafili in USBiocon Biologics has reached a settlement and licensing agreement with Regeneron, clearing the way for the US commercialization of Yesafili...15 Apr, 2025, 10.53 AM IST- USFDA approves Biocon Biologics' biosimilar product to treat ophthalmology conditionsBiocon Biologics received US Food and Drug Administration (USFDA) approval for biosimilar Yesafili, a vascular endothelial growth factor in...21 May, 2024, 12.12 PM IST
- Roche launches top selling eye drug Vabysmo in IndiaRoche Pharma India launches Vabysmo, a medication for neovascular age-related macular degeneration and diabetic macular edema in India. The...05 Mar, 2024, 10.14 PM IST
- Biocon Biologics settles patent issue; paves way for launch of biosimilar product in CanadaBiocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalm...04 Mar, 2024, 11.47 AM IST
- Lupin ties up with Amman Pharma for commercialisation of biosimilar productLupin has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries inc...10 Nov, 2023, 04.43 PM IST
Load More
